melanoma
We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.
We have treated 45 patients with V600 mutated <span class="disease" id="23237741-5-46-54">melanoma</span> including patients with V600R mutation between July 2011 and October 2012 with the selective <span class="gene" id="23237741-5-148-152">BRAF</span> inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.